New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology’s annual meeting, Dec. 5-8, including: Actinium, ADC, Affimed, Agios, Allogene, Allovir, Aptose, Arcellx, Aruvant, Ascentage, Astrazeneca, Autolus, Bluebird, Blueprint, Bristol Myers, Cardiff, Carsgen, Celyad, CTI, Curis, Dcprime, Editas, Elevatebio, Equillium, Erytech, Fate, Forma, Geron, Gilead, Gracell, GT, Imago, Imara, Incyte, Innocare, Innovent, Janssen, Beigene, Biosight, Jubilant, Karyopharm, Kymera, Kyowa Kirin, Lilly, Liminal, Morphosys, Nektar, Neximmune, Novartis, Nurix, Orchard, Phosplatin, Precigen, Roche, Sierra Oncology, Sutro, TG, Trillium, Triphase.

New data on a variety of blood disorder therapies announced at the 62nd American Society of Hematology (ASH) annual meeting moved company shares on Dec. 7. Shares of Fate Therapeutics Inc. (NASDAQ:FATE) hit a record high, rising 37.8% to $83.77 by day's end on news of clinical activity for one candidate in refractory diffuse large B-cell lymphoma.

There will be plenty of data from clinical trials testing treatments for various lymphomas at the 62nd American Society of Hematology (ASH) annual meeting this weekend. While CAR T cells have changed the landscape in the relapsed and refractory space for large B-cell lymphoma patients with two FDA approved medications, Kymriah (tisagenlecleucel, Novartis AG) and Yescarta (axicabtagene ciloleucel, Gilead Sciences), "the uptake has been good but not dominant. There's still plenty of space. There's still plenty of need," Jason Westin, leader of the diffuse large B-cell lymphoma research team at the University of Texas MD Anderson Cancer Center in the Department of Lymphoma and Myeloma, said on a call with clients from Raymond James.

New and updated preclinical and clinical data presented by biopharma firms at the American Society of Hematology’s annual meeting, Dec. 5-8, including: In8bio, Incyte, Jannsen, Rigel.

Despite challenges tossed at the phase III study of mitapivat from Agios Pharmaceuticals Inc. by COVID-19, top-line data showed the oral therapy hit its primary endpoint in treating adults with pyruvate kinase (PK) deficiency who don’t receive regular transfusions.

Positive top-line data from the pivotal phase III study of AAV5-based etranacogene dezaparvovec by Uniqure NV, shows 54 patients met the primary endpoint in treating severe to moderate hemophilia B.

Shares of Bluebird Bio Inc. (NASDAQ:BLUE) sank 16.6%, or $9.72, to close at $48.83 as Wall Street reacted to news that the U.S. regulatory filing for Lentiglobin in sickle cell disease (SCD) will be delayed. Previously expected in the second half of next year, the filing won’t happen until late 2022.

An earlier-than-intended release of abstracts for the American Society of Hematology annual meeting spilled multiple market-moving updates Nov. 4, though with no apparent shocks so far. Shares of Allogene Therapeutics Inc. sunk 8% on Nov. 4 over some metered disappointment around initial data for ALLO-715, a potential medicine for relapsed/refractory (r/r) multiple myeloma. By contrast, shares of Global Blood Therapeutics Inc. climbed nearly 15%, buoyed by new data supporting the long-term use of its sickle cell disease therapy, Oxbryta (voxelotor).